<div id="readability-page-1"><div> <div> , /PRNewswire/ -- Glancy Prongay Wolke &amp; Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Atara Biotherapeutics, Inc. (&#34;Atara&#34; or the &#34;Company&#34;) (NASDAQ: ATRA). IF YOU SUFFERED A LOSS ON YOUR ATARA BIOTHERAPEUTICS INVESTMENTS, CLICK HERE BEFORE MAY 22, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About? The complaint filed alleges that, between May 20, 2024 and January 9, 2026, Defendants failed to disclose to investors that: (1) certain manufacturing issues, as well as deficiencies inherent in the ALLELE study, made it unlikely that the FDA would approve the tabelecleucel BLA; (2) accordingly, tabelecleucel's regulatory prospects were overstated; (3) the aforementioned manufacturing issues also subjected Atara to a heightened risk of regulatory scrutiny, as well as jeopardized its ongoing clinical trials; (4) all the foregoing was likely to have a significant negative impact on Atara's business and financial condition; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Charles Linehan, Esq., Glancy Prongay Wolke &amp; Rotter LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: [email protected] Telephone: 310-201-9150 (Toll-Free: 888-773-9224) Visit our website at www.glancylaw.com. Follow us for updates on LinkedIn, Twitter, or Facebook. If you inquire by email, please include your mailing address, telephone number and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Contact Us: Glancy Prongay Wolke &amp; Rotter LLP, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067 Charles Linehan Email: [email protected] Telephone: 310-201-9150 Toll-Free: 888-773-9224 Visit our website at: www.glancylaw.com. SOURCE Glancy Prongay Wolke &amp; Rotter LLP <img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTA4Jk5ld3NJdGVtSWQ9TEE1NTI4MCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MDgxNjQxUFJfTkVXU19VU1BSX19fX19MQTU1Mjgw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTA4Jk5ld3NJdGVtSWQ9TEE1NTI4MCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MDgxNjQxUFJfTkVXU19VU1BSX19fX19MQTU1Mjgw"/></div> </div></div>

ATRA

Glancy Prongay Wolke & Rotter LLP has announced that shareholders of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) who suffered financial losses have the opportunity to lead a securities fraud class action lawsuit. The lawsuit alleges that between May 20, 2024, and January 9, 2026, the company failed to disclose significant manufacturing issues and regulatory risks that misled investors about its business prospects. Interested investors can participate before the lead plaintiff deadline of May 22, 2026.

prnewswire

Atara Biotherap

SPDR S&P Biotech

iShares US Pharma

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Ark Genomic Revolution ETF

iShares Global Healthcare

VanEck Biotech ETF

ALPS Medical Breakthrough

Health Care Select Sector SPDR

16:41 ETAtara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit